SCHEMBL65022

SCHEMBL65022

COc1ccccc1COC=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.58
CHRM2 P08172 10/20 0.50
CHRM1 P11229 3/20 0.50
CHRM3 P20309 2/20 0.50
TAAR1 Q96RJ0 1/20 0.48
ALDH1A1 P00352 2/20 0.47
ABCB1 P08183 1/20 0.47
GRIN1 Q05586 4/20 0.46
GRIN2A Q12879 4/20 0.46
BCHE P06276 4/20 0.46
ACHE P22303 4/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
CHRM4 P08173 1/20 0.46
CYP3A4 P08684 1/20 0.46
CHRM5 P08912 1/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2093125 0.84 ABCB1 (0.50) ALDH1A1ABCB1L3MBTL1KDM4ECYP3A4
SCHEMBL2095156 0.82 IDO1 (0.60) IDO1CHRM2CHRM1CHRM3TAAR1
SCHEMBL12884720 0.82 IDO1 (0.43) IDO1CHRM2CHRM1CHRM3TAAR1
Ethoxycarbonyl Group SCHEMBL28233663 0.81 CHRM2 (0.47) IDO1CHRM2CHRM1CHRM3TAAR1
SCHEMBL11406620 0.81 SRC (0.40) IDO1CHRM2CHRM1CHRM3ALDH1A1
SCHEMBL14306607 0.81 IDO1 (0.58) IDO1CHRM2CHRM1CHRM3TAAR1
SCHEMBL2088633 0.80 FFAR4 (0.46) IDO1ALDH1A1ACHEKDM4ETP53
SCHEMBL5778566 0.79 IDO1 (0.56) IDO1CHRM2CHRM1CHRM3TAAR1
SCHEMBL6666899 0.79 PTGS2 (0.46) ALDH1A1KDM4ETSHR
SCHEMBL2096470 0.78 TLR2 (0.43) IDO1CHRM2CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117049954-A Preparation method of vanillin 万华化学集团股份有限公司 2023-11-14 CN claimed
US-11919838-B2 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 Reata Pharmaceuticals Holdings, LLC (US) 2024-03-05 US disclosed
US-11911395-B2 Methods of treating obesity using antioxidant inflammation modulators Reata Pharmaceuticals Holdings, LLC (US) 2024-02-27 US disclosed
WO-2023250339-A2 VLA4 INHIBITORS AND USES THEREOF WASHINGTON UNIVERSITY (US) 2023-12-28 WO disclosed
CN-117049954-A Preparation method of vanillin 万华化学集团股份有限公司 2023-11-14 CN disclosed
CN-117049954-A Preparation method of vanillin 万华化学集团股份有限公司 2023-11-14 CN disclosed
US-11814338-B2 Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators REATA PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
WO-2023212746-A2 A UNIFIED STRATEGY FOR THE TOTAL SYNTHESES OF ERIBULIN AND A MACROLACTAM ANALOGUE OF HALICHONDRIN B WILLIAM MARSH RICE UNIVERSITY (US) 2023-11-02 WO disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-20230303503-A1 CELL ACTIVATABLE IRON CHELATORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-09-28 US disclosed
EP-0911336-A1 PYRIDONECARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1999-04-28 EP disclosed
US-5817669-A A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1998-10-06 US disclosed
EP-0812838-A1 PYRIDONECARBOXYLIC ACID DERIVATIVE SUBSTITUTED BY BICYCLIC AMINO GROUP, ESTER THEREOF, SALT THEREOF, AND BICYCLIC AMINE AS INTERMEDIATE THEREFOR DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1997-12-17 EP disclosed
EP-0787726-A1 NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1997-08-06 EP disclosed
WO-1991011448-A1 THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1991-08-08 WO disclosed
US-4370334-A VASODILATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-25 US disclosed
US-4338322-A 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-07-06 US disclosed
US-4284634-A HYPOTENSIVE VASODILATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-08-18 US disclosed
US-4259350-A PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK SANKYO COMPANY LIMITED (JP) 1981-03-31 US disclosed
US-4145432-A 6-ACYLORYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND A METHOD OF EFFECTING VASODILATION THEREWITH FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11911395-B2 Methods of treating obesity using antioxidant inflammation modulators TXNRD2, HMOX1, GPX4 IDO1 887/4885CHRM2 1876/4885CHRM1 2345/4885
US-11919838-B2 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 IL17A, ALOX15, ALOX12 IDO1 221/4885CHRM2 2961/4885CHRM1 2249/4885
US-11814338-B2 Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators GPX4, MPO, GPX1 IDO1 615/4885CHRM2 3898/4885CHRM1 3900/4885
US-20230303503-A1 CELL ACTIVATABLE IRON CHELATORS TFRC, SLC40A1, FECH IDO1 305/4885CHRM2 4849/4885CHRM1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.